NG-641

· Akamis Bio

Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for NG-641, covering 2025-03-24 to 2025-03-24. Get the full timeline:

Most recent: Clinical Trial Update: A Study of NG-641 and Pembrolizumab in Squamous Cell Carcinoma of the Head and Neck [Phase 1]